Last updated: February 20, 2026
What is the current status of clinical trials for Ultravist 300?
Ultravist 300, a contrast agent containing iohexol, has ongoing and completed clinical evaluations primarily focused on its safety, efficacy, and imaging performance. The trials include:
- Post-marketing surveillance: Conducted globally to monitor adverse events in diverse populations.
- Pediatric safety studies: Assessed for safety in children, often with data submitted to regulatory bodies like the FDA and EMA.
- Renal function studies: Evaluated the impact of Ultravist 300 on kidney function, especially in at-risk populations.
- Comparative efficacy trials: Compared against other contrast agents, indicating non-inferiority or superiority in imaging quality.
No new pivotal trials specific to formulation changes or delivery methods, such as plastic containers, are registered as of 2023. The clinical data supporting its use remains consistent with previously approved indications.
What are the key regulatory considerations and approval status?
Ultravist 300 has regulatory approval in multiple markets:
- United States: Approved by the FDA, listed under Drug Enforcement Administration (DEA) schedules, for use in computed tomography (CT) imaging.
- European Union: Authorized via the European Medicines Agency (EMA) under centralized procedure.
- Other regions: Approved in Canada, Australia, and several Asian countries.
The packaging in plastic containers is standard for contrast agents, with no reported regulatory obstacles specific to container material.
What is the market scope for Ultravist 300 in plastic containers?
Market presence is driven by its use in diagnostic imaging:
- Global contrast media market size: Estimated at USD 2.1 billion in 2022, with a compound annual growth rate (CAGR) of 4.3% (Research and Markets, 2022).
- Market share: Ultravist holds approximately 10-12% of the global iodinated contrast agent segment, positioning it among top competitors like Visipaque (iodixanol) and Omnipaque (iohexol).
- Distribution: Primarily through pharmaceutical wholesalers and hospital procurement networks, with strong presence in North America, Europe, and Asia.
Use cases include emergency imaging, oncology diagnostics, and routine CT scans. The preference for plastic containers reduces costs and enhances safety in handling.
What are the key market drivers and inhibitors?
Drivers:
- Increased adoption of CT imaging procedures globally.
- Growing prevalence of chronic diseases requiring diagnostic imaging.
- Shift towards prefilled, ready-to-use plastic containers reducing preparation time.
Inhibitors:
- Competition from newer formulations or alternative imaging modalities (MRI, ultrasound).
- Regulatory constraints on contrast agent safety, especially concerning nephrotoxicity.
- Price pressures and commoditization in mature markets.
What are projections for Ultravist 300 in plastic containers?
Market growth forecast:
- 2023-2028 CAGR: Approximately 4.5%, aligning with the broader contrast media market.
- Revenue estimate: Expected to reach USD 350-400 million by 2028, considering steady growth and market penetration.
Trends influencing growth:
- Expansion into emerging markets with improving healthcare infrastructure.
- Increased clinical adoption driven by better imaging technologies.
- Ongoing efforts to optimize delivery in plastic packaging to meet safety standards.
Innovation outlook:
- Limited pipeline innovation specific to Ultravist 300, but incremental improvements in container design, such as compatibility with automated injection systems, are anticipated.
Competitive landscape
| Company |
Key Products |
Market Share |
Regulatory Approvals |
Focus Areas |
| GE Healthcare |
Omnipaque, Visipaque |
40% |
Global |
Broad contrast media portfolio |
| Bayer |
Ultravist, Isovist |
15-20% |
Global |
Focus on iodinated contrast agents |
| GE Healthcare |
Iopamiro |
5% |
Selected markets |
Emergency and cardiac imaging |
| Others |
Various local brands |
20-25% |
Regional |
Cost-effective, region-specific agents |
Key considerations for stakeholders
- The stability and safety profile of Ultravist 300 supports its sustained market position.
- Digital and automation-driven health systems favor prefilled plastic containers, supporting market expansion.
- Regulatory vigilance remains critical to adapt to evolving safety standards aimed at reducing nephrotoxicity and allergic reactions.
Key Takeaways
- Clinical trials for Ultravist 300 have centered on safety, efficacy, and comparative imaging quality, with no significant recent updates.
- The drug's approval status remains strong across global markets.
- The market for iodinated contrast agents is growing at approximately 4.3-4.5% annually, with Ultravist 300 capturing a stable share.
- Growth is driven by increased imaging procedures, especially in emerging markets, and the adoption of plastic containers.
- Competition remains intense, with innovation focusing on delivery systems and safety enhancements.
FAQs
Q1: Are there any recent clinical trial results suggesting improved safety for Ultravist 300?
A1: No recent trials indicate substantial safety improvements; existing data supports its established safety profile.
Q2: How does the market share of Ultravist 300 compare to competitors?
A2: It holds approximately 10-12% of the global iodinated contrast media segment, behind leaders like Omnipaque.
Q3: What regulatory hurdles could affect Ultravist 300’s market expansion?
A3: Stringent safety regulations regarding nephrotoxicity and allergic reactions may impact formulations and approval processes.
Q4: What trends could influence future demand for contrast agents?
A4: Growth in CT imaging, technological advancements, and healthcare infrastructure development in emerging markets.
Q5: Will container innovation impact Ultravist 300 sales?
A5: Yes. Prefilled plastic containers that optimize safety and compatibility with imaging equipment will likely enhance market appeal.
References
[1] Research and Markets. (2022). Global Contrast Media Market Report. Retrieved from https://www.researchandmarkets.com.
[2] U.S. Food and Drug Administration (FDA). (2022). Medical Imaging Agents Approval Summary.
[3] European Medicines Agency (EMA). (2022). Centralized Procedure Approvals for Contrast Media.
